Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
CT Senate Passes Sweeping Consumer Protection Bill The Connecticut Senate passed an expansive consumer protection bill ( SB 5 ). Among other things, the measure would require service providers such as...
Social Media Warning Label Legislation Catching on in States Although Congress hasn’t responded to former U.S. Surgeon General Vivek Murthy’s call last June to take up legislation requiring...
OR Lawmakers Pass Age Discrimination Bill Oregon’s legislature passed a bill ( HB 3187 ) that would prohibit an employer from requesting an applicant’s age, date of birth or date of graduation...
WI Assembly Passes Multiple Healthcare Bills Wisconsin’s Assembly passed multiple healthcare-related bills with broad bipartisan support. One ( AB 43 ) would allow pharmacists to prescribe birth...
A nightmare may be coming to life for social media companies in Minnesota. There, Democrats in the state Legislature have embraced a pioneering bill, SB 3197 , which seeks to levy the nation’s...
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.